Literature DB >> 21088744

Aquaretics in the treatment of ascites.

Lennox Jeffers1.   

Abstract

Entities:  

Year:  2010        PMID： 21088744      PMCID： PMC2976860     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN： 1554-7914


× No keyword cloud information.
  5 in total

1.  A multicenter, open-label, dose-ranging study to exploratively evaluate the efficacy, safety, and dose-response of tolvaptan in patients with decompensated liver cirrhosis.

Authors:  Kiwamu Okita; Isao Sakaida; Mitsuru Okada; Akira Kaneko; Kazuaki Chayama; Michio Kato; Michio Sata; Harumasa Yoshihara; Naomasa Yoshihara; Noriyuki Ono; Yoshikazu Murawaki
Journal:  J Gastroenterol       Date:  2010-04-13       Impact factor: 7.527

2.  Effects of a selective vasopressin V2 receptor antagonist, satavaptan, on ascites recurrence after paracentesis in patients with cirrhosis.

Authors:  Florence Wong; Pere Gines; Hugh Watson; Yves Horsmans; Paolo Angeli; Paul Gow; Pascal Minini; Mauro Bernardi
Journal:  J Hepatol       Date:  2010-05-24       Impact factor: 25.083

3.  Effects of satavaptan, a selective vasopressin V(2) receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: a randomized trial.

Authors:  Pere Ginès; Florence Wong; Hugh Watson; Slobodan Milutinovic; Luis Ruiz del Arbol; Dan Olteanu
Journal:  Hepatology       Date:  2008-07       Impact factor: 17.425

4.  Successful long-term treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone secretion with satavaptan (SR121463B), an orally active nonpeptide vasopressin V2-receptor antagonist.

Authors:  Alain Soupart; Peter Gross; Jean-Jacques Legros; Sándor Alföldi; Djillali Annane; Hassan M Heshmati; Guy Decaux
Journal:  Clin J Am Soc Nephrol       Date:  2006-10-11       Impact factor: 8.237

5.  Clinical trial: short-term effects of combination of satavaptan, a selective vasopressin V2 receptor antagonist, and diuretics on ascites in patients with cirrhosis without hyponatraemia--a randomized, double-blind, placebo-controlled study.

Authors:  P Ginès; F Wong; H Watson; R Terg; R Bruha; J-P Zarski; F Dudley
Journal:  Aliment Pharmacol Ther       Date:  2010-01-22       Impact factor: 8.171
  5 in total
  1 in total

1.  Refractory ascites-the contemporary view on pathogenesis and therapy.

Authors:  Beata Kasztelan-Szczerbinska; Halina Cichoz-Lach
Journal:  PeerJ       Date:  2019-10-15       Impact factor: 2.984
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.